Afatinib is currently in phase III testing to investigate whether this second‐generation EGFR‐TKI can improve clinical outcomes for NSCLC patients with uncommon mutations compared with platinum doublet chemotherapy.19 The gene discussed is EGFR; the disease is non-small cell lung carcinoma.